Evidence map›Paper›PMID 39009925›Full record

ReviewJournal of endocrinological investigation2024

Inositols and female reproduction disorders: a consensus statement from the working group of the Club of the Italian Society of Endocrinology (SIE)-Women's Endocrinology.

Costanzo Moretti, Marco Bonomi, Paola Dionese, Silvia Federici, Anna Maria Fulghesu, Jacopo Giannelli, Roberta Giordano, Laura Guccione, Elisa Maseroli, Paolo Moghetti and 8 more

Abstract readReviewConsensus Statement
PubMed Publisher
In one paragraph

Review in Journal of endocrinological investigation, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

  1. Article
  2. Delphi consensus on the diagnostic criteria of polycystic ovary syndrome.Journal of endocrinological investigation · 2025
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

18 authors.

Costanzo MorettiDepartment of Systems' Medicine, University of Rome Tor Vergata, Rome, Italy.
Marco BonomiDepartment of Medical Biotechnology and Translational Medicine, University of Milan, Milan, Italy.
Paola DioneseDivision of Endocrinology and Diabetes Prevention and Care, Department of Medical and Surgical Sciences (DIMEC), IRCCS Azienda Ospedaliero-Universitaria of Bologna, Bologna, Italy.
Silvia FedericiDepartment of Medical Biotechnology and Translational Medicine, University of Milan, Milan, Italy.
Anna Maria FulghesuDepartment of Surgical Science, Duilio Casula Hospital, University of Cagliari, Monserrato, Cagliari, Italy.
Jacopo GiannelliDivision of Endocrinology, Diabetes and Metabolism, Department of Medical Sciences, University of Turin, Turin, Italy.
Roberta GiordanoDepartment of Biological and Clinical Sciences, University of Turin, Turin, Italy.
Laura GuccioneDepartment of Systems' Medicine, University of Rome Tor Vergata, Rome, Italy.
Elisa MaseroliAndrology, Women's Endocrinology and Gender Incongruence Unit, Department of Experimental and Clinical Biomedical Sciences, Mario Serio Careggi University Hospital, Florence, Italy.
Paolo MoghettiUnit of Endocrinology, Diabetes and Metabolism, Department of Medicine, University of Verona, Verona, Italy.
Roberto MioniDepartment of Medicine, Clinica Medica 3-Azienda Ospedaliera, University of Padua, Padua, Italy.
Rosario PivonelloDipartimento di Medicina Clinica e Chirurgica, Sezione di Endocrinologia, Università Federico II di Napoli, Naples, Italy.
Chiara SabbadinEndocrinology Unit, Department of Medicine (DIMED), University Hospital of Padua, Padua, Italy.
Carla ScaroniEndocrinology Unit, Department of Medicine (DIMED), University Hospital of Padua, Padua, Italy.
Massimo TonaccheraDepartment of Endocrinology, Pisa University Hospital of Cisanello, Azienda Ospedaliera Universitaria, Pisa, Italy.
Nunzia VerdeDipartimento di Medicina Clinica e Chirurgia, Sezione di Endocrinologia, Diabetologia, Andrologia e Nutrizione, Unità di Andrologia e Medicina della Riproduzione, Sessualità e Affermazione di Genere, Università Federico II di Napoli, Naples, Italy.
Linda VignozziAndrology, Women's Endocrinology and Gender Incongruence Unit, Department of Experimental and Clinical Biomedical Sciences, Mario Serio Careggi University Hospital, Florence, Italy.
Alessandra GambineriDivision of Endocrinology and Diabetes Prevention and Care, Department of Medical and Surgical Sciences (DIMEC), IRCCS Azienda Ospedaliero-Universitaria of Bologna, Bologna, Italy. alessandra.gambiner3@unibo.it.ORCID http://orcid.org/0000-0003-2242-6734

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

purposeTo provide the latest scientific knowledge on the efficacy of inositols for improving reproductive disorders in women with and without polycystic ovary syndrome (PCOS) and to reach a consensus on their potential use through a Delphi-like process.

methodsA panel of 17 endocrinologists and 1 gynecologist discussed 4 key domains: menses irregularity and anovulation, fertility, pregnancy outcomes, and neonatal outcomes.

resultsA total of eight consensus statements were drafted. Myo-inositol (Myo) supplementation can be used to improve menses irregularities and anovulation in PCOS. Myo supplementation can be used in subfertile women with or without PCOS to reduce the dose of r-FSH for ovarian stimulation during IVF, but it should not be used to increase the clinical pregnancy rate or live birth rate. Myo supplementation can be used in the primary prevention of gestational diabetes mellitus (GDM), but should not be used to improve pregnancy outcomes in women with GDM. Myo can be preconceptionally added to folic acid in women with a previous neural tube defects (NTD)-complicated pregnancy to reduce the risk of NTDs in newborns. Myo can be used during pregnancy to reduce the risk of macrosomia and neonatal hypoglycemia in mothers at risk of GDM.

conclusionThis consensus statement provides recommendations aimed at guiding healthcare practitioners in the use of inositols for the treatment or prevention of female reproductive disorders. More evidence-based data are needed to definitively establish the usefulness of Myo, the appropriate dosage, and to support the use of D-chiro-inositol (DCI) or a definitive Myo/DCI ratio.

Indexed as

InositolPolycystic Ovary SyndromeConsensusDiabetes, GestationalDietary SupplementsEndocrinologyFemaleHumansInfertility, FemaleItalyPregnancyPregnancy ComplicationsPregnancy OutcomeSocieties, MedicalInositolDelphi consensusFertilityNeonatal outcomesOvulationPregnancy outcomes

Identifiers

PMID39009925

What Socratic holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.